Psoriasis Market Positioned for Strong Growth Through 2034, DelveInsight Finds

The Psoriasis market in the 7MM was valued at approximately USD 34 billion in 2025 and is projected to grow at a steady CAGR of 1.70% during the forecast period (2025–2034). DelveInsight's comprehensive market research provides critical insights into such market trends, enabling stakeholders to understand growth drivers, emerging opportunities, and potential challenges within the Psoriasis landscape.

By analyzing historical data, current market dynamics, and future projections, DelveInsight equips pharmaceutical companies, investors, and healthcare professionals with actionable intelligence to make informed strategic decisions, identify investment opportunities, optimize product positioning, and plan research and development initiatives effectively.

The Psoriasis market is increasingly guided by therapeutic innovation and biologic advancement. IL-23 inhibitors and IL-17 inhibitors represent highly lucrative segments, highlighted by blockbuster treatments like SKYRIZI and COSENTYX. These biologic therapies have demonstrated superior efficacy and safety profiles compared to conventional systemic treatments, reshaping the treatment landscape for moderate to severe psoriasis.

DelveInsight's report, "Psoriasis Market Insights, Epidemiology, and Market Forecast-2034," provides a comprehensive analysis of the Psoriasis landscape. The report delivers detailed insights into the disease, including historical and projected epidemiology, helping stakeholders understand the prevalence, incidence, and patient demographics across key regions.

Additionally, it examines Psoriasis market dynamics, offering a thorough assessment of current and emerging market trends, treatment patterns, and therapeutic developments. The analysis spans major markets, including the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan, equipping decision-makers with actionable intelligence for strategic planning, investment, and research initiatives.

To know in detail about the Psoriasis market outlook, drug uptake, treatment scenario and epidemiology trends, visit Psoriasis Market Forecast.

Some of the key facts of the Psoriasis Market Report:

• Key Psoriasis Companies: UCB Pharma, Novartis, Janssen, AstraZeneca, Organon Pharmaceuticals, Takeda/Nimbus Therapeutics, Johnson & Johnson Innovative Medicine/Protagonist Therapeutics, Alumis, Can-Fite BioPharma, SFA Therapeutics, and others
• Key Psoriasis Therapies: BIMZELX (bimekizumab), COSENTYX (secukinumab), TREMFYA (guselkumab), SKYRIZI (risankizumab), ILUMYA (tildrakizumab), TALTZ (ixekizumab), SILIQ (brodalumab), ENBREL (etanercept), REMICADE (infliximab), HUMIRA (adalimumab), CIMZIA (certolizumab), STELARA (ustekinumab), VTAMA (tapinarof), Zasocitinib (TAK-279), Icotrokinra (JNJ-77242113), ESK-001, SFA-002, Piclidenoson (CF101), and others
• The Psoriasis market is expected to grow due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various emerging Psoriasis pipeline products will significantly revolutionize the Psoriasis market dynamics.

Psoriasis Overview

Psoriasis is a chronic (long-lasting) disease in which the immune system becomes overactive, causing skin cells to multiply too quickly. Patches of skin become scaly and inflamed, most often on the scalp, elbows, or knees, but other parts of the body can be affected as well. The symptoms of psoriasis can sometimes go through cycles, flaring for a few weeks or months followed by periods when they subside or go into remission. Psoriasis affects approximately 125 million people worldwide, making it a significant public health concern. There are many ways to treat psoriasis, and treatment plans are tailored to the type and severity of disease, often starting with topical therapies and progressing to systemic and biologic options when needed.

Key Trends in Psoriasis Therapeutics Market:

• Rising Adoption of Biologic Therapies: Increasing use of TNF-α inhibitors, IL-23 inhibitors, and IL-17 inhibitors as first-line and combination treatments for moderate to severe psoriasis.
• Biologic Innovation and Efficacy: Tumor necrosis factor-alpha (TNF-α) inhibitors (including ENBREL, REMICADE, and HUMIRA), IL-23 inhibitors (like TREMFYA, SKYRIZI, and ILUMYA), and IL-17 inhibitors (such as COSENTYX, TALTZ, and SILIQ) are revolutionizing psoriasis care with superior tolerability and sustained efficacy.
• Emergence of Oral Therapies: Development of oral agents such as zasocitinib (a TYK2 inhibitor showing up to one-third complete clearance rates), icotrokinra (first targeted oral peptide blocking IL-23 receptor), and ESK-001 offer convenient alternatives to injectable biologics without compromising efficacy.
• Personalized Treatment Approaches: Enhanced diagnostic capabilities and shared decision-making balancing efficacy, safety, convenience, preferences, and economic considerations for individualized therapy selection.
• Treatment Switching Patterns: Real-world data show that treatment switching in psoriasis is common, with many patients transitioning from oral therapies to biologics like HUMIRA, STELARA, or ENBREL, often due to better efficacy or tolerability, reflecting evolving preferences toward treatments offering long-term control, safety, and convenience.
• Growing Pipeline of Emerging Therapies: Novel development pipeline including zasocitinib (Takeda/Nimbus Therapeutics), icotrokinra (Johnson & Johnson Innovative Medicine and Protagonist Therapeutics), and ESK-001 (Alumis), among others, expanding treatment options.

Psoriasis Epidemiology

The report on Psoriasis epidemiology provides a comprehensive analysis of the disease's prevalence, incidence, and patient demographics. It includes age- and gender-specific distribution, regional and global trends, and data on location-specific and severity-specific subtypes. The report also highlights risk factors, disease burden, and projections for future trends, helping stakeholders understand the scope of Psoriasis and plan targeted interventions, research, and treatment strategies.

Psoriasis Epidemiology Segmentation:

The Psoriasis market report proffers epidemiological analysis for the study period 2025–2034 in the 7MM segmented into:

• Total Diagnosed Prevalent Cases of Psoriasis in the 7MM
• Type-specific Diagnosed Prevalent Cases of Psoriasis in the 7MM
• Location-specific Diagnosed Prevalent Cases of Psoriasis in the 7MM
• Severity-specific Diagnosed Prevalent Cases of Psoriasis in the 7MM

Download the report to understand which factors are driving Psoriasis epidemiology trends @ Psoriasis Epidemiology Forecast.

Recent Developments In The Psoriasis Treatment Landscape:

• In March 2025, SFA Therapeutics announced the presentation of two head-to-head preclinical studies of its oral psoriasis treatment candidate, SFA-002, at the American Academy of Dermatology Annual Meeting in Orlando, Florida, demonstrating promising efficacy profiles.
• In March 2025, UCB announced further long-term data from the Phase III trials and their open-label extensions, investigating BIMZELX in adults with moderate-to-severe plaque psoriasis was presented as six posters at the 2025 American Academy of Dermatology (AAD) annual meeting in Orlando, Florida, highlighting sustained long-term efficacy.
• In March 2025, Alumis announced positive 52-week results from its Phase II trial of ESK-001, an oral TYK2 inhibitor for moderate-to-severe plaque psoriasis. The data, presented at the AAD Annual Meeting, showed sustained or improved skin clearance, itch relief, and quality of life, with no new safety concerns.
• In April 2025, Johnson & Johnson released new icotrokinra data from a subgroup analysis of ICONIC-LEAD in moderate-to-severe plaque psoriasis to assess the efficacy and safety of systemic therapy in adolescents and adults simultaneously. These data were presented at the 2025 World Conference on Psoriasis and Dermatology (WCPD) annual meeting, demonstrating efficacy across diverse patient populations.

Psoriasis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Psoriasis market or expected to get launched during the study period. The analysis covers Psoriasis market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Psoriasis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Psoriasis Therapies and Key Companies

• BIMZELX (bimekizumab): UCB Pharma – IL-17A/F inhibitor for moderate-to-severe plaque psoriasis
• COSENTYX (secukinumab): Novartis – IL-17A inhibitor with rapid skin clearance
• TREMFYA (guselkumab): Janssen – IL-23 inhibitor with favorable safety profile
• SKYRIZI (risankizumab): AstraZeneca – IL-23 inhibitor with sustained efficacy
• ILUMYA (tildrakizumab): Novartis – IL-23 inhibitor well-tolerated biologic
• TALTZ (ixekizumab): Eli Lilly – IL-17A inhibitor
• SILIQ (brodalumab): LEO Pharma – IL-17 receptor antagonist
• ENBREL (etanercept): Pfizer – TNF-α inhibitor
• REMICADE (infliximab): Janssen – TNF-α inhibitor
• HUMIRA (adalimumab): AbbVie – TNF-α inhibitor
• CIMZIA (certolizumab): UCB Pharma – TNF-α inhibitor
• STELARA (ustekinumab): Johnson & Johnson – IL-12/23 inhibitor
• VTAMA (tapinarof): Organon Pharmaceuticals – Aryl hydrocarbon receptor agonist
• Zasocitinib (TAK-279): Takeda/Nimbus Therapeutics – TYK2 inhibitor in Phase III trials
• Icotrokinra (JNJ-77242113): Johnson & Johnson Innovative Medicine/Protagonist Therapeutics – IL-23 receptor antagonist
• ESK-001: Alumis – TYK2 inhibitor in Phase II trials
• SFA-002: SFA Therapeutics – Oral psoriasis therapy
• Piclidenoson (CF101): Can-Fite BioPharma – Oral therapy in development

To know more about Psoriasis companies working in the treatment market, visit @ Psoriasis Clinical Trials and Therapeutic Assessment.

Psoriasis Market Drivers

• Increasing prevalence of Psoriasis globally and growing patient awareness due to emerging therapies
• Growth of biologic therapies offering superior efficacy and safety profiles for moderate-to-severe psoriasis
• Rising adoption of precision medicine and personalized treatment approaches
• Development of oral therapeutic options providing convenient alternatives to injectable biologics
• Advancements in diagnostic approaches and understanding of psoriasis pathophysiology
• Growing geriatric population with higher psoriasis prevalence
• Expansion of treatment switching patterns favoring biologic therapies with improved outcomes
• Healthcare policy support and reimbursement improvements for biologic treatments

Psoriasis Market Barriers

• High cost of biologic therapies limiting patient access in emerging markets
• Reimbursement challenges and restricted formulary access in certain healthcare systems
• Long-term safety concerns and immunogenicity risks with biologic treatments
• Competition from multiple therapeutic options complicating treatment selection
• Limited awareness in certain regions regarding available treatment options
• Biosimilar competition impacting market pricing and patient access patterns
• Complex patient journey requiring specialty pharmacy networks and patient support programs
• Variability in treatment response due to genetic and immunological factors

Scope of the Psoriasis Market Report

• Study Period: 2025–2034
• Coverage: 7MM [The United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]
• Key Psoriasis Companies: UCB Pharma, Novartis, Janssen, AstraZeneca, Organon Pharmaceuticals, Takeda/Nimbus Therapeutics, Johnson & Johnson Innovative Medicine/Protagonist Therapeutics, Alumis, Can-Fite BioPharma, SFA Therapeutics, and others
• Key Psoriasis Therapies: BIMZELX, COSENTYX, TREMFYA, SKYRIZI, ILUMYA, TALTZ, SILIQ, ENBREL, REMICADE, HUMIRA, CIMZIA, STELARA, VTAMA, Zasocitinib, Icotrokinra, ESK-001, SFA-002, Piclidenoson, and others
• Psoriasis Therapeutic Assessment: Psoriasis current marketed and Psoriasis emerging therapies
• Psoriasis Market Dynamics: Psoriasis market drivers and Psoriasis market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Psoriasis Unmet Needs, KOL's views, Analyst's views, Psoriasis Market Access and Reimbursement

Discover more about therapies set to grab major Psoriasis market share @ Psoriasis Treatment Market.